Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$2.18
-0.5%
$2.18
$1.98
$4.48
$99.65M0.5394,103 shs46,995 shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.05
-4.4%
$0.08
$0.05
$1.25
$2.19M-0.0680,895 shs10,781 shs
PolyPid Ltd. stock logo
PYPD
PolyPid
$4.90
+1.9%
$5.05
$3.57
$13.50
$23.52M1.416,286 shs202 shs
Venus Concept Inc. stock logo
VERO
Venus Concept
$0.68
-11.6%
$0.81
$0.60
$4.70
$4.33M0.66442,207 shs15,755 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-0.45%+6.31%+1.86%+3.79%-47.10%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-12.78%-28.96%-33.10%-38.65%-92.69%
PolyPid Ltd. stock logo
PYPD
PolyPid
+6.42%+11.86%-0.62%-26.56%-63.18%
Venus Concept Inc. stock logo
VERO
Venus Concept
+6.66%-8.46%+9.05%-37.99%-73.56%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
1.3605 of 5 stars
3.51.00.00.00.62.50.6
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
2.302 of 5 stars
3.50.00.04.50.01.70.0
PolyPid Ltd. stock logo
PYPD
PolyPid
1.0518 of 5 stars
0.05.00.00.02.41.70.6
Venus Concept Inc. stock logo
VERO
Venus Concept
2.0266 of 5 stars
0.05.00.00.02.93.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
3.00
Buy$3.5060.55% Upside
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.504,512.55% Upside
PolyPid Ltd. stock logo
PYPD
PolyPid
3.00
BuyN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
2.00
HoldN/AN/A

Current Analyst Ratings

Latest PYPD, KRMD, VERO, and NMRD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$28.52M3.49N/AN/A$0.45 per share4.84
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K27.34N/AN/A($0.41) per share-0.13
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/A($1.27) per shareN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
$76.35M0.06N/AN/A($2.43) per share-0.28

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$13.74M-$0.29N/AN/AN/A-48.18%-27.82%-21.30%5/1/2024 (Confirmed)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$23.86M-$19.68N/AN/AN/AN/A-450.37%-101.27%5/8/2024 (Confirmed)
Venus Concept Inc. stock logo
VERO
Venus Concept
-$37.25M-$6.85N/AN/AN/A-48.79%N/A-36.21%5/15/2024 (Confirmed)

Latest PYPD, KRMD, VERO, and NMRD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/AN/A  
5/8/2024N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$1.96N/A+$1.96N/AN/AN/A  
5/1/2024N/A
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04N/A+$0.04N/AN/AN/A  
4/1/2024Q4 2023
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A-$2.01-$2.01-$2.01N/A$18.13 million
3/13/2024Q4 2023
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04-$0.02+$0.02$0.12$7.01 million$7.19 million
2/14/2024Q4 2023
PolyPid Ltd. stock logo
PYPD
PolyPid
-$2.17-$3.97-$1.80-$3.97N/AN/A
2/12/2024Q3 2024
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A-$0.12-$0.12-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/AN/A
Venus Concept Inc. stock logo
VERO
Venus Concept
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
0.02
4.55
3.77
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
PolyPid Ltd. stock logo
PYPD
PolyPid
2.17
0.83
0.83
Venus Concept Inc. stock logo
VERO
Venus Concept
N/A
2.13
1.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
58.60%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
PolyPid Ltd. stock logo
PYPD
PolyPid
26.47%
Venus Concept Inc. stock logo
VERO
Venus Concept
87.41%

Insider Ownership

CompanyInsider Ownership
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
25.60%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
PolyPid Ltd. stock logo
PYPD
PolyPid
24.70%
Venus Concept Inc. stock logo
VERO
Venus Concept
51.39%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
8245.71 million34.01 millionOptionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
PolyPid Ltd. stock logo
PYPD
PolyPid
594.80 million3.61 millionNo Data
Venus Concept Inc. stock logo
VERO
Venus Concept
3046.36 million3.09 millionNot Optionable

PYPD, KRMD, VERO, and NMRD Headlines

SourceHeadline
Venus Concept Announces Loan Purchase and Completion of First Phase of RefinancingVenus Concept Announces Loan Purchase and Completion of First Phase of Refinancing
finance.yahoo.com - April 24 at 7:48 PM
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
globenewswire.com - April 15 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Inc.: Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
finanznachrichten.de - April 9 at 1:29 AM
Venus Concept Announces Approval For Venus Bliss MAX In Israel - Quick FactsVenus Concept Announces Approval For Venus Bliss MAX In Israel - Quick Facts
markets.businessinsider.com - April 8 at 10:21 AM
Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAXVenus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX
globenewswire.com - April 8 at 7:30 AM
Ranking every single MoonSwatch thats ever droppedRanking every single MoonSwatch that's ever dropped
gq-magazine.co.uk - April 3 at 10:37 PM
On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?On heels on Vero Beach, Sebastian growth, Fellsmere population to double in five years?
news.yahoo.com - April 3 at 10:37 PM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
finance.yahoo.com - April 3 at 7:36 AM
Venus Concept Announces Australian Regulatory Approval for Venus Versa ProVenus Concept Announces Australian Regulatory Approval for Venus Versa Pro
globenewswire.com - April 3 at 7:30 AM
Venus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Inc.: Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
finanznachrichten.de - April 2 at 9:35 PM
VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023VERO Stock Earnings: Venus Concept Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 1 at 1:03 PM
Venus Concept: Q4 Earnings SnapshotVenus Concept: Q4 Earnings Snapshot
houstonchronicle.com - April 1 at 9:42 AM
Venus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsVenus Concept Announces Fourth Quarter and Fiscal Year 2023 Financial Results
globenewswire.com - April 1 at 7:00 AM
Venus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Inc.: Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
finanznachrichten.de - March 26 at 2:33 AM
Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing RulesVenus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules
globenewswire.com - March 25 at 7:30 AM
Venus Concept Launches "NEXThetics" ProgramVenus Concept Launches "NEXThetics" Program
stockhouse.com - March 13 at 10:30 AM
Venus Concept Launches “NEXThetics” ProgramVenus Concept Launches “NEXThetics” Program
globenewswire.com - March 12 at 4:05 PM
Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 27 at 4:05 PM
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesVenus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
globenewswire.com - February 23 at 8:00 AM
Nasdaq Surges 300 Points; NVIDIA Posts Strong ResultsNasdaq Surges 300 Points; NVIDIA Posts Strong Results
msn.com - February 23 at 1:09 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
finance.yahoo.com - February 22 at 10:08 AM
Venus Concept Announces CE Mark for Venus Versa Pro in EuropeVenus Concept Announces CE Mark for Venus Versa Pro in Europe
globenewswire.com - February 22 at 7:30 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
finance.yahoo.com - February 20 at 10:42 AM
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
globenewswire.com - February 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

KORU Medical Systems logo

KORU Medical Systems

NASDAQ:KRMD
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
PolyPid logo

PolyPid

NASDAQ:PYPD
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Venus Concept logo

Venus Concept

NASDAQ:VERO
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.